AOD-9604 in Evanston — Fat Loss Peptide Research Guide
AOD-9604 research guide for Evanston. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Evanston Investigators
For anyone in Evanston looking to source AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. This global online supply model is actually an advantage for quality — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. This guide guides Evanston researchers through that evaluation process and explains what quality documentation for AOD-9604 should look like.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Evanston comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying AOD-9604: Quality Markers to Look For
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. A COA for AOD-9604 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Evanston researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is standard practice in the community. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order AOD-9604 — ships to Evanston
COA-verified · International tracking · Research grade
All use of AOD-9604 in Evanston or anywhere constitutes research use — this compound is not approved for therapeutic human application, and all handling should comply with standard research safety practices. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. The primary quality-related safety risk in AOD-9604 research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the key safeguard. PubMed are the primary literature resources for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
